$0.68
1.45% yesterday
Nasdaq, Nov 21, 10:11 pm CET
ISIN
US8112921015
Symbol
SCYX

SCYNEXIS, Inc. Stock price

$0.68
-0.10 12.82% 1M
-0.09 11.78% 6M
-0.53 43.80% YTD
-0.51 42.86% 1Y
-1.81 72.69% 3Y
-5.28 88.59% 5Y
-66.87 98.99% 10Y
-89.32 99.24% 20Y
Nasdaq, Closing price Fri, Nov 21 2025
-0.01 1.45%
ISIN
US8112921015
Symbol
SCYX
Industry

Key metrics

Basic
Market capitalization
$28.5m
Enterprise Value
$-9.4m
Net debt
positive
Cash
$37.9m
Shares outstanding
42.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
9.7 | 1.6
EV/Sales
negative | negative
EV/FCF
0.3
P/B
0.8
Financial Health
Equity Ratio
60.8%
Return on Equity
-38.7%
ROCE
-81.3%
ROIC
-438.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.9m | $17.5m
EBITDA
- | -
EBIT
$-34.6m | $-21.8m
Net Income
$-25.3m | $-16.9m
Free Cash Flow
$-33.6m
Growth (TTM | estimate)
Revenue
-65.8% | 367.9%
EBITDA
- | -
EBIT
33.6% | 41.2%
Net Income
30.6% | 20.6%
Free Cash Flow
-53.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-1,181.1%
Net
-862.9% | -96.4%
Free Cash Flow
-1,145.7%
More
EPS
$-0.5
FCF per Share
$-0.8
Short interest
3.2%
Employees
28
Rev per Employee
$130.0k
Show more

Is SCYNEXIS, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

SCYNEXIS, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a SCYNEXIS, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a SCYNEXIS, Inc. forecast:

Buy
89%
Hold
11%

Financial data from SCYNEXIS, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
2.93 2.93
66% 66%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
16% 16%
529%
- Research and Development Expense 22 22
33% 33%
753%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -35 -35
34% 34%
-1,182%
Net Profit -25 -25
31% 31%
-863%

In millions USD.

Don't miss a Thing! We will send you all news about SCYNEXIS, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SCYNEXIS, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
JERSEY CITY, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has completed the transfer of the BREXAFEMME (ibrexafungerp) New Drug Application (NDA) to GSK.
Neutral
GlobeNewsWire
16 days ago
JERSEY CITY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the third quarter ended September 30, 2025.
Neutral
GlobeNewsWire
about one month ago
JERSEY CITY, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $22 million payment from GlaxoSmithKline Intellectual Property (No. 3) Limited (GSK) as part of a resolution of the disagreement with GSK relate...
More SCYNEXIS, Inc. News

Company Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Head office United States
CEO David Gonzalez
Employees 28
Founded 1999
Website www.scynexis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today